{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:18:27Z","timestamp":1792135107544,"version":"4.4.0"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T00:00:00Z","timestamp":1508457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Teratogenic medications increase risks of miscarriage, fetal death, and\/or birth defects. It is important to identify whether women of childbearing potential are taking these medications and to minimize exposure to these agents through change in drug therapy before conception and\/or use of effective contraception to prevent conception.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the utility of reproductive life plans as tools to identify women using potentially teratogenic medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review was conducted on reproductive life plans completed by women receiving services as part of the Toledo\u2010Lucas County Healthy Start program. The medication section of the reproductive life plan was reviewed to determine: if it was completed; categories of medications reported (prescription, over\u2010the\u2010counter, vitamin\/herbal); potentially teratogenic medications listed; contraception use and method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Medication lists were completed for 437 of the 580 reproductive life plans reviewed (75%). Thirty\u2010five women (8%) reported use of a potentially teratogenic medication; most commonly reported agents included blood pressure medications and antidepressants. Only 10 women taking a potentially teratogenic medication (29%) reported using some form of contraception, half of which reported use of a less effective method such as condoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The reproductive life plan can be a useful tool to identify women of childbearing age who require intervention due to use of potentially teratogenic medications. Efforts are needed to ensure complete and accurate reporting of medication use in reproductive life plans, and to promote effective contraceptive use among women taking potentially teratogenic medications.<\/jats:p><\/jats:sec>","DOI":"10.1111\/birt.12318","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T06:32:48Z","timestamp":1508481168000},"page":"50-54","source":"Crossref","is-referenced-by-count":5,"title":["Utility of reproductive life plans in identification of potentially teratogenic medication use: A pilot study"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-5281","authenticated-orcid":false,"given":"Natalie","family":"DiPietro Mager","sequence":"first","affiliation":[{"name":"Pharmacy Practice Ohio Northern University Raabe College of Pharmacy  Ada OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Mills","sequence":"additional","affiliation":[{"name":"University of Toledo College of Pharmacy and Pharmaceutical Sciences  Toledo OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Snelling","sequence":"additional","affiliation":[{"name":"Maternal and Child Health Toledo\u2010Lucas County Health Department  Toledo OH USA"},{"name":"ProMedica Physicians Group  Toledo OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,20]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6909.2010.01203.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-2011.2011.00048.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001314"},{"key":"e_1_2_5_5_1","first-page":"1","article-title":"Recommendations to improve preconception health and health care\u2014United States: a report of the CDC\/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR Surveill Summ"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.08.031"},{"key":"e_1_2_5_7_1","unstructured":"U.S. Food and Drug Administration.Pregnancy and lactation labeling (drugs) final rule. 2014.https:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/labeling\/ucm093307.htm. Accessed July 13 2017."},{"key":"e_1_2_5_8_1","unstructured":"Centers for Disease Control and Prevention.Preconception health and health care: exposures. 2014.https:\/\/www.cdc.gov\/preconception\/careforwomen\/exposures.html. Accessed July 13 2017."},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2015.01.014"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420350215"},{"key":"e_1_2_5_11_1","volume-title":"Women's Health Across the Lifespan: A Pharmacotherapeutic Approach","author":"Borget LM","year":"2010"},{"key":"e_1_2_5_12_1","first-page":"30831","article-title":"Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling","volume":"73","author":"U.S. Food and Drug Administration","year":"2008","journal-title":"Fed Reg"},{"key":"e_1_2_5_13_1","unstructured":"Centers for Disease Control and Prevention.Infant health.2017.http:\/\/www.cdc.gov\/nchs\/fastats\/infant-health.htm. Accessed July 13 2017."},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12054"},{"key":"e_1_2_5_15_1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bmj.306.6876.499","article-title":"What proportion of congenital abnormalities can be prevented?","volume":"306","author":"Czeizel AE","year":"1996","journal-title":"Br Med J"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10995-006-0102-2"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.02.029"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/birt.12177"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2016.10.004"},{"key":"e_1_2_5_20_1","unstructured":"World Health Organization.Family planning\/Contraception.2017.http:\/\/www.who.int\/mediacentre\/factsheets\/fs351\/en\/. Accessed September 12 2017."}],"container-title":["Birth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbirt.12318","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/birt.12318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T19:13:06Z","timestamp":1695755586000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/birt.12318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,20]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/birt.12318"],"URL":"https:\/\/doi.org\/10.1111\/birt.12318","archive":["Portico"],"relation":{},"ISSN":["0730-7659","1523-536X"],"issn-type":[{"value":"0730-7659","type":"print"},{"value":"1523-536X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,20]]}}}